Targeting Complement Factor BB as a Selective Inhibitor of the Alternative Pathway

Time: 4:10 pm
day: Conference Day One


  • SAR443809 selectively binds to Factor Bb and inhibits the complement alternative pathway, but not classical or lectin pathways
  • SAR443809 inhibits AP activity by blocking the cleavage of C3 and Factor B
  • The selectivity and efficacy of SAR443809 confer a robust pharmacodynamic response for the treatment of AP mediated disorders.